CagriSema helps women lose 25% of their weight in study
Novo continues to build the case for its new weight-loss candidate CagriSema, pointing to new data that show strong efficacy in women.
Newsletters and Deep Dive digital magazine
Novo continues to build the case for its new weight-loss candidate CagriSema, pointing to new data that show strong efficacy in women.
Trials of Lilly's Omvoh, Gilead's emvistegrast, Takeda's Entyvio, AbbVie's ABBV-466, and Sanofi/Teva's duvakitug are highlights of UEGW.
AstraZeneca has launched a project with tech giant Oracle that will use AI and real-world data to improve clinical research and patient care.
A year after signing a first deal with Hansoh worth up to $1.45 billion, Roche has returned for another that could be more than 10 times larger.
Merck KGaA is slated to acquire UK-based Silence Therapeutics in a $1.3bn deal that would give it a late-stage drug for polycythemia vera.
Editor's Picks
Newsletters and Deep Dive
digital magazine